Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolio

Hong Kong's IPO market braces for China Tower debut after string of poor starts

Published 07/08/2018, 05:00
Updated 07/08/2018, 05:10
© Reuters. Sign of China Tower Corp is seen at the PT Expo China in Beijing
HK50
-
0388
-
1810
-
4385
-
ADYEN
-
1672
-
0788
-
6160
-

By Jennifer Hughes and Donny Kwok

HONG KONG (Reuters) - Hong Kong is readying to host the world's biggest initial public offering (IPO) in two years on Wednesday, as China Tower Corp Ltd (HK:0788) debuts in a market with record IPO numbers but where recent floats have struggled to maintain issue prices.

The world's largest operator of mobile telecommunications towers last week priced its shares at HK1.26 each, the bottom of its indicative range, to raise $6.9 billion (5.33 billion pounds).

That took the amount raised by companies listing in Hong Kong in 2018 to $22.4 billion, in the city's best performance by this point in the year, showed data from Thomson Reuters. That makes it the world's leading centre for capital raising, ahead of second-placed New York Stock Exchange at $20.6 billion.

However, China Tower's IPO comes just weeks after other notable deals struggled upon debut.

Chinese smartphone maker Xiaomi Corp (HK:1810) suffered a weak debut in early July after raising $4.7 billion. The stock recovered to trade as much as 30 percent above its IPO price but has since slipped to just 1.2 percent higher at $17.22.

Earlier this month, Ascletis Pharma Inc (HK:1672) became the first firm to list under new rules for biotech startups, having raised $400 million. Its shares began trading on Wednesday but had fallen as much as 31 percent by Friday. On Monday, they were trading at HK$10.9, down 22 percent from their issue price.

"Stocks like Xiaomi which aimed for a higher valuation, and Ascletis, which is seen a lead for biotechs in testing valuation, both failed to impress and that will make it harder for upcoming IPOs to take any aggressive approach in pricing," said Steven Leung, a sales director at broker UOB Kay Hian.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Nasdaq-listed Beigene Ltd (HK:6160) will become the second biotech to list under the new rules when it floats on Wednesday after raising $903 million.

Market participants said broader market weakness has not helped, with investors fretting over the potential impact of Sino-U.S. tit-for-tat import tariffs. The benchmark Hang Seng share price index has lost 3.5 percent since the start of July.

"Particularly strong risk appetite is required for IPOs in the current climate," said Alex Wong, a director of asset management at Ample Capital.

This year, 159 firms have applied to list on the Hong Kong stock exchange's Main Board, putting 2018 on course to be the IPO market's busiest year in at least a decade, showed data from bourse operator Hong Kong Exchanges and Clearing Ltd (HK:0388).

However, no Hong Kong stock currently features in the year's top 20 first-day IPO gains worldwide.

Of firms selling over $500 million worth of shares, payments processor Adyen NV (AS:ADYEN) jumped 90 percent on its Amsterdam debut in June, showed data from Dealogic. Online flea market operator Mercari Inc (T:4385) added 77 percent on its first day in Tokyo.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.